Abstract Library

#4257 Tolerability and outcomes of neuroendocrine tumors treated with peptide receptor radionuclide therapy and stereotactic body radiation therapy

Introduction: The addition of stereotactic body radiation therapy (SBRT) to patients treated with PRRT may provide synergistic benefit by targeting specific sites of disease that represent areas of tumor heterogeneity. Little is known regarding the efficacy or potential toxicity of this approach. A retrospective review of patients with NEN treated with sequential PRRT and SBRT was performed to provide preliminary outcome and toxicity data to inform further combined treatment strategies.

Conference:

Presenting Author: Myrehaug S

Authors: Nunez Rodriguez J, Ng S, Chen H, Singh S, Hallet J,

Keywords: PRRT, Radiation, SABR, SBRT,

#3739 Local tumor control in patients with neuroendocrine neoplasms treated with stereotactic ablative radiotherapy (SBRT)

Introduction: Neuroendocrine neoplasms (NEN) represent a diverse group of malignancies. Anatomic origin, histology and biological behaviour vary extensively. The treatment armamentarium includes surgery (first choice when possible), systemic therapy and localised treatment modalities. The role of radiotherapy is not yet established, but studies indicate that local tumor control (LTC) can be achieved by high-dose radiotherapy. Stereotactic ablative radiotherapy (SBRT) is high doses of radiation delivered to a small target, with potential of achieving local tumor control.

Conference:

Presenting Author:

Authors: Nygaard Dowler A, Aggerholm Pedersen N, Knap Marquard M, Dam G, Tabaksblat E,

Keywords: neuroendocrine, stereotactic radiotherapy, sbrt, local control,